Effects of traditional Chinese medicine compound formula WCAP and its sub⁃formulas on subcutaneous transplanted tumor nude mouse model of human pancreatic cancer and IL⁃6/STAT3 signaling pathway
|更新时间:2023-05-16
|
Effects of traditional Chinese medicine compound formula WCAP and its sub⁃formulas on subcutaneous transplanted tumor nude mouse model of human pancreatic cancer and IL⁃6/STAT3 signaling pathway
Shanghai Journal of Traditional Chinese MedicineVol. 57, Issue 5, Pages: 80-86(2023)
CAO Nida,LI Zhaoyan,HUA Fengchun,et al.Effects of traditional Chinese medicine compound formula WCAP and its sub⁃formulas on subcutaneous transplanted tumor nude mouse model of human pancreatic cancer and IL⁃6/STAT3 signaling pathway[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(5):80-86.
CAO Nida,LI Zhaoyan,HUA Fengchun,et al.Effects of traditional Chinese medicine compound formula WCAP and its sub⁃formulas on subcutaneous transplanted tumor nude mouse model of human pancreatic cancer and IL⁃6/STAT3 signaling pathway[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(5):80-86. DOI: 10.16305/j.1007-1334.2023.2208046.
Effects of traditional Chinese medicine compound formula WCAP and its sub⁃formulas on subcutaneous transplanted tumor nude mouse model of human pancreatic cancer and IL⁃6/STAT3 signaling pathway
Objective,2,To study the effects of traditional Chinese medicine (TCM) compound formula WCAP and its sub-formulas on the tumor growth of subcutaneous transplanted human pancreatic cancer BxPC-3 cells in nude mice and on the interleukin-6/signal transducer and activator transcription 3 (IL-6/STAT3) signaling pathway.,Methods,2,The subcutaneous transplanted tumor model of human pancreatic cancer BxPC-3 cells in nude mice was established. Totally 30 SPF-grade nude mice were randomly divided into 6 groups of 5 mice each, which were blank control group, 5-fluorouracil(5-FU) group, compound group, spleen-invigorating group (SI group), heat-clearing and toxicity-removing group (HCTR group), and hardness-resolving group (HR group). The tumor quality and tumor growth inhibition rate of the subcutaneous transplanted tumor in each group of nude mice were recorded. The mRNA and protein expression levels of IL-6/STAT3 pathway and its downstream target genes ,c,-,myc, cyclin D1, VEGF and MMP,-,2, were detected in tumor tissues by real-time fluorescence quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot, respectively.,Results,2,①Each intervention group showed lower tumor weight than that of control group. The 5-FU group, compound group and each sub-formula group could inhibit the growth of subcutaneous transplanted tumor in nude mice (,P,<,0.05), and the tumor growth inhibition rate of the compound group was higher than that of each sub-formula group(,P,<,0.05). ②The mRNA expression levels of IL-6/STAT3 pathway and its downstream target genes, c,-,myc, cyclin D1, VEGF, and ,MMP,-,2, were lowered in the 5-FU group, compound group and HR group than those in the control group (,P,<,0.05). ③Compared with those in the control group, the protein expression levels of IL-6/STAT3 pathway and its downstream target genes c-myc, cyclin D1, VEGF, and MMP-2 were lowered in the 5-FU group and compound group (,P,<,0.05), and the protein expression levels of c-myc, MMP-2, and IL-6 were lowered in HR group (,P,<,0.05).,Conclusions,2,WCAP compound formula could inhibit the tumor growth of subcutaneous transplanted human pancreatic cancer BxPC-3 cells in nude mice, and the mechanism was related to the inhibition of IL-6/STAT3 pathway and regulation of the expression levels of its downstream target genes ,c,-,myc,, ,cyclin D1,, ,VEGF,, and ,MMP,-,2,. WCAP compound formula showed a better effect on the tumor growth inhibition rate, mouse weight, and IL-6/STAT3 pathway and its downstream target gene regulation than each sub-formula group.
关键词
胰腺癌中药复方白介素-6/信号转导和激活剂转录3信号通路裸小鼠皮下移植瘤模型中药研究
Keywords
pancreatic cancertraditional Chinese medicine compound formulaIL-6/STAT3 pathwaysubcutaneous transplanted tumor model in nude micetraditional Chinese herbal medicine research
references
ZHENG R, ZHANG S, ZENG H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9.
GOLDSTEIN D, SPRY N, CUMMINS M M, et al. The GOFURTGO study: AGITG phase Ⅱ study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer[J]. Br J Cancer, 2012, 106(1): 61-69.
UENO H, IOKA T, IKEDA M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013, 31(13): 1640-1648.
CONROY T, DESSEIGNE F, YCHOU M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19):1817-1825.
VON HOFF D D, ERVIN T, ARENA F P, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18): 1691-1703.
MOORE M J, GOLDSTEIN D, HAMM J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trial Group[J]. J Clin Oncol, 2007, 25(15): 1960-1966.
GOLAN T, HAMMEL P, RENI M, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4): 317-327.
ZHANG J, LI Z, LIU L, et al. Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway[J]. Hepatology, 2018, 67(1):171-187.
NISHIHARA M, OGURA H, UEDA N, et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+Th with a minimum effect on that of Treg in the steady state[J]. Int Immunol, 2007, 19(6): 695-702.
JIANG M , WANG Y , ZHANG H , et al. IL-37 inhibits invasion and metastasis in non-small cell lung cancer by suppressing the IL-6/STAT3 signaling pathway[J]. Thorac Cancer, 2018, 9(5): 621-629.
LIU C, DONG L, SUN Z, et al. Esculentoside a suppresses breast cancer stem cell growth through stemness attenuation and apoptosis induction by blocking IL-6/STAT3 signaling pathway[J]. Phytother Res, 2018, 32(11): 2299-2311.
ZHENG X, XU M, YAO B, et al. IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment[J]. Cell Signal, 2016, 28(9): 1314-1324.
SHEN W, YUAN Y, ZHAO M, et al. Novel long non-coding RNA GACAT3 promotes gastric cancer cell proliferation through the IL-6/STAT3 signaling pathway[J]. Tumor Biol, 2016, 37(11):14895-14902.
YANG H, ZHANG J, LI J, et al. Overexpression of miR-574-3p suppresses proliferation and induces apoptosis of chronic myeloid leukemia cells via targeting IL6/JAK/STAT3 pathway[J]. Exp Ther Med, 2018, 16(5): 4296-4302.
CAO N, ZHAO A, ZHAO G, et al. Survival analysis of 272 patients with pancreatic cancer undergoing combined treatment[J]. Integr Cancer Ther, 2015, 14 (2): 133-139.
TANIGUCHI K, KARIN M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer[J]. Semin Immunol, 2014, 26(1): 54-74.
ZHOU Q X, JIANG X M, WANG Z D, et al. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis[J]. Med Oncol, 2015, 32(4): 105.
RUIZ GARCIA Y, PABON-MARTINEZ Y V, SMITH C I E, et al. Specific dsDNA recognition by a mimic of the DNA binding domain of the c-Myc/Max transcription factor[J]. Chem Commun (Camb), 2017, 53(49): 6653-6656.
WU G, YUAN M, SHEN S, et al. Menin enhances c-Myc-mediated transcription to promote cancer progression[J]. Nat Commun, 2017, 8: 15278.
MAURO L, PELLEGRINO M, GIORDANO F, et al. Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells[J]. FASEB J, 2015, 29(5): 2150-2160.
ZHANG Y, SU Y, ZHAO Y, et al. MicroRNA-720 inhibits pancreatic cancer cell proliferation and invasion by directly targeting cyclin D1[J]. Mol Med Rep, 2017, 16(6): 9256-9262.
ZHAO D, PAN C, SUN J, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate myc and sox2[J]. Oncogene, 2015, 34(24):3107-3119.